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Abstract
Objective: Sleep disturbances are prevalent in human tauopathies yet despite
the importance of sleep, little is known about its relationship with tau pathology. Here, we investigate this interaction by analyzing sleep and tau pathology
throughout tauopathy disease progression in P301S human tau transgenic mice.
Methods: P301S and wild-type mice were analyzed by electroencephalography
(EEG)/electromyography at 3, 6, 9, and 11 months of age for sleep/wake time,
EEG power, and homeostatic response. Cortical volume and tau pathology was
also assessed by anti-phospho-tau AT8 staining. Results: P301S tau mice had
significantly decreased rapid eye movement (REM) sleep at 9 months of age
and decreased REM and non-REM (NREM) sleep as well as increased wakefulness at 11 months. Sleep loss was characterized by fewer wake, REM, and
NREM bouts, increased wake bout duration, and decreased sleep bout duration.
Decreased REM and NREM sleep was associated with increased brainstem tau
pathology in the sublaterodorsal area and parafacial zone, respectively. P301S
mice also showed increased EEG power at 6 and 9 months of age and decreased
power at 11 months. Decreased EEG power was associated with decreased cortical volume. Despite sleep disturbances, P301S mice maintained homeostatic
response to sleep deprivation. Interpretation: Our results indicate that tau
pathology is associated with sleep disturbances that worsen with age and these
changes may be related to tau pathology in brainstem sleep regulating regions
as well as neurodegeneration. Tau-induced sleep changes could affect disease
progression and be a marker for therapeutic efficacy in this and other
tauopathy models.

Introduction
Abnormal phosphorylation and aggregation of the microtubule-binding protein tau is a hallmark of a class of neurodegenerative diseases known as tauopathies. Tauopathies
include diseases such as Alzheimer’s disease (AD), which
is characterized by aggregation of tau and amyloid-b (Ab),
some forms of frontotemporal dementia (FTD) such as
Pick’s disease, and pure tauopathies such as progressive
supranuclear palsy (PSP) and corticobasal degeneration.
Sleep disturbances are prevalent in tauopathies with up to
76% of FTD and 67% of AD patients exhibiting clinical
sleep disturbances of some kind and as many as 20% of PSP
patients displaying rapid eye movement (REM) sleep specific disorders.1,2 Although varied in presentation and
180

pathology, tauopathies are associated with an overall
decrease in sleep.3–7 Sleep disturbance is one of the leading
causes of institutionalization in AD, however, the direct
effect of tau pathology on sleep remains poorly understood.8
Tau abnormalities are among the earliest observable
neurodegenerative pathologies associated with AD and in
both AD and PSP tau pathology is prevalent in sleep centers of the brain.9–13 For example, AD-type tau pathology
is shown to begin accumulating in the brainstem early in
life, with 70% of 20–30 year olds studied having abnormal tau pathology in the locus coeruleus (LC).9,10 Early
abnormal tau pathology progresses to other parts of the
brainstem and hypothalamus, including many sleep regulating regions, prior to any cortical detection of tau or Ab
aggregation.9,11 In AD, decreases in sleep efficiency
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precede the onset of dementia, while reduced sleep and
increased sleep fragmentation are associated with an
increased risk of developing AD.14–16 Tau pathology in
sleep regions of the brain may play a role in these preclinical AD sleep disturbances. Furthermore, tau pathology
develops in sleep-regulating brain regions throughout the
clinical course of AD and PSP, suggesting that tau pathology could also play a role in the severity of sleep disturbances in clinical tauopathy disease progression.6,12,13,17,18
Sleep disturbances have been identified in mice expressing both tau and amyloid pathology as well as mice
expressing tau pathology alone in the forebrain.19–22 Furthermore, tau knockout mice have decreased sleep suggesting that loss of endogenous tau function may also
contribute to sleep disturbances.23 However, the direct
effect of tau pathology throughout the brain on sleep has
not been studied. To determine if tau pathology alone is
sufficient to alter sleep we characterized sleep over time
in a mouse model of FTD with Parkinsonism linked to
chromosome 17 containing a human tau transgene with
the P301S mutation. We further investigate tau pathology
in brainstem sleep regions of P301S Tau transgenic (tg)
mice over time to determine if pathology in these areas
may contribute to changes in sleep.

Altered Sleep and EEG Power in P301S Tau Mice

and habituated for 3 days after which EEG/EMG was
recorded for 2 days. For sleep deprivation studies, a third
day of recording was conducted in which mice were manually kept awake by gentle touching with a paintbrush for
6 h following lights on and further recorded for five more
hours to test homeostatic response. During recording, mice
were disturbed only during the 1 h prior to lights off, this
time was omitted from all analysis. EEG and EMG signals
were acquired by a P511K A.C. Preamplifier (Grass-Telefactor Instruments, Warwick, RI USA), digitized with a DigiData 1440A Data Acquisition System (Molecular Devices,
Sunnyvale, CA USA), and recorded digitally using pClamp
10.2 (Molecular Devices).

EEG/EMG analysis and statistics

Male P301S mice and wild-type (WT) littermates were
studied at 3–4, 6–7, 9–10, and 11–12 months of age.
P301S mice (PS19) contain a human tau transgene with a
P301S mutation on the B6C3 background and were
obtained from Jackson Labs (Bar Harbor, ME USA).24
Mice were housed in a 12 h light/dark cycle with food
ad libitum. All animal procedures and studies were
approved by the Animal Studies Committee at Washington University School of Medicine.

EEG/EMG recordings were scored manually for wake,
non-rapid eye movement (NREM) sleep, and REM sleep in
10 second epochs using SleepSign (Kissei Comtec Co., Ltd,
Matsumoto Japan) and all statistics performed in Graphpad
Prism 5 (GraphPad Software Inc., La Jolla, CA USA) unless
otherwise stated. Sleep time was averaged over 2 days
(23 h/day) and significance at each age determined by Student’s t-test. Sleep/wake bout number and duration analysis
as well as power analysis was completed on day 2 of recording only. Significance in bout number and duration at each
time point was determined by Student’s t-test. FFT significance was determined by two-way analysis of variance
(ANOVA) and followed with Bonferroni post hoc when a
significant interaction was observed. In power analysis, two
P301S outliers were detected using Grubb’s test (GraphPad
QuickCalcs) between all P301S animals at that time point.
Animals excluded from analysis include one 6 month animal
for NREM power only and one 11 month animal for REM
power only. For sleep deprivation studies, sleep time and
power for 5 h following sleep deprivation was normalized to
the previous day and analyzed as stated above. All data are
expressed as mean  standard error of the mean (SEM).

EEG sleep/wake monitoring

Immunohistochemistry

Electroencephalography (EEG)/electromyography (EMG)
sleep/wake monitoring was performed as previously
described.22,25 EEG was recorded by stainless steel bone
screws placed over the right frontal bone (Bregma:
+1.0 mm, 1.0 mm lateral to midline) and right parietal
bone (Bregma: 3.0 mm, 2.5 mm lateral to midline) and
EMG recorded from two electrode wires placed on the right
and left neck musculature. All signals were grounded to a
bone screw electrode placed over the cerebellum midline.
Following electrode implantation, mice were housed in
12 h light/dark conditions for 10 days. Mice were transferred to EEG/EMG cages, attached to recording cables,

Following the recording session mice were anesthetized
with pentobarbatol (200 mg/kg, i.p.) and perfused with
cold Dulbecco’s phosphate-buffered saline (PBS) with heparin (3 U/mL). The left brain hemisphere was fixed in 4%
paraformaldehyde and cryoprotected in 30% sucrose in
PBS. Brain hemispheres were sliced coronally in 30 lm sections from the most rostral region of the cortex caudally
through the brain stem using a freezing slice microtome.
Sections were stored at 20°C in cryoprotectant (0.2 mol/
L PBS, 30% sucrose, 30% ethylene glycol) until use.
Immunohistochemistry was performed in five batches
that each contained a control sample for normalization.

Methods
Animals
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Every sixth hemisphere section was selected from the rostral cortex through the brainstem and placed in netwells
(6 slices/well). Slices were washed three times for 5 min in
Tris-buffered saline (TBS), incubated in 0.3% hydrogen
peroxide in TBS for 10 min, and washed three times. Samples were then blocked for 1 h in 3% milk in TBS with
0.25% triton (vol/vol) (TBS-X) and incubated overnight at
4°C with biotinylated AT8 antibody (1:500, Thermo-Fisher,
Rockford, IL USA) in 1% milk in TBS-X. AT8 recognizes
tau phosphorylated at Ser202 and Thr205.26 Following antibody incubation, slices were washed, bound to avidin using
Vectastain ABC elite (Vector Laboratories, Burlingame, CA
USA), washed, and developed in DAB (Sigma, St. Louis,
MO USA). Slices were mounted on gelatin coated slides
and rehydrated in increasing concentrations of ethanol and
xylene. All samples were imaged using a Nanozoomer slide
scanner (Hamamatsu Photonics, Hamamatsu Japan).

Cortex volume and tau pathology analysis
AT8-stained slices were used to determine cortex volume
and tau pathology. Cortex volume was determined using
NDP viewer (Hamamatsu Photonics). Every sixth slice
was analyzed from the crossing of the corpus callosum
(Bregma: +1.1 mm) to the dorsal end of the hippocampus (Bregma: 3.9 mm) and volume was determined
stereologically. Significance was determined by one-way
ANOVA with Tukey’s post hoc. To analyze tau pathology, slices were converted to gray scale and analyzed
using ImageJ (National Institutes of Health, Bethesda,
MD, USA). For each region a threshold was determined
to accurately depict positive staining and the percent area
covered determined by ImageJ. One slice/animal was used
to determine pathology in the sublaterodorsal area (SLD)
(approximately Bregma: 5.3 mm) and parafacial zone
(PZ) (approximately Bregma: 5.6 mm) and three slices/
animal separated by 180 lm used to determine entorhinal cortex and piriform cortex area pathology (approximately Bregma:
1.75,
1.93,
2.11). All % area
covered values were normalized to appropriate staining
control to eliminate batch variation. Significant differences between age points were determined by one-way
ANOVA with Tukey’s post hoc and significant correlation
identified by Pearson r.

Results
P301S Tau tg mice have decreased sleep,
increased wakefulness, and disrupted sleep
architecture that worsens with age
P301S Tau tg mice display a progressive development of
tau phosphorylation and aggregation with onset of tau
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pathology around 5 months of age and brain atrophy
beginning around 8 months.24 To determine if tau pathology throughout the brain is sufficient to alter sleep, P301S
and WT mice at 3 months (prepathology), 6 months (early
pathology), 9 months (late pathology, early atrophy), and
11 months (late pathology, late atrophy) of age were analyzed by EEG/EMG recording and the amount of time
spent in wake, REM sleep, and NREM sleep quantified. No
significant changes in sleep or wake time were observed
between genotypes at 3 or 6 months of age (Fig. 1). At
9 months of age, REM sleep was significantly decreased by
28% in P301S compared to WT mice but no changes were
observed in wake or NREM sleep (Fig. 1). Loss of REM
sleep worsened at 11 months of age with P301S REM sleep
decreased 61% compared to WT mice (Fig. 1B). In addition to changes in REM sleep, 11 month P301S mice
showed a significant decrease in NREM sleep and a significant increase in wake (Fig. 1A and C). Despite loss of sleep
time, P301S mice maintained circadian sleep rhythms with
increased sleep during light periods compared to dark and
increased wake during dark periods compared to light, suggesting that these changes in sleep time are not due to lack
of circadian regulation (data not shown).
The observed changes in sleep time were associated
with altered wake, REM, and NREM bout number as well
as bout duration. P301S mice had significantly fewer wake
bouts and significantly longer wake bout duration at both
9 and 11 months of age (Fig. 2A and D). These results
demonstrate that P301S mice do not transition out of
wake into sleep states as often as WT mice, suggesting a
breakdown in sleep-generating/wake-inhibiting pathways
in P301S mice. Furthermore, decreased REM sleep in
P301S mice (Fig. 1B) was associated with fewer REM
bouts at 9 and 11 months of age and a shorter REM bout
duration at 11 months (Fig. 2B and E). NREM bouts
were also affected with significantly fewer entries into
NREM sleep at 9 and 11 months of age, which was countered by increased NREM bout duration at 9 months but
not at 11 months (Fig. 2C and F). Taken together, these
changes demonstrate that sleep architecture is significantly
disrupted in P301S mice beginning by 9 months of age
and sleep disturbances worsen with disease progression.

Decreased REM and NREM sleep in P301S
Tau tg mice is associated with tau
pathology in brainstem sleep regulating
regions
In tauopathies, sleep regulating regions of the brain accumulate tau pathology and in AD specifically, tau pathology
develops in many regions prior to cortical tau or amyloid
aggregation.9,11–13 To test if tau pathology in sleep centers
of the brain may contribute to sleep disturbances in P301S
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Tau tg mice we analyzed tau pathology, as identified by AT8
staining, in 3-, 6-, 9-, and 11-month-old P301S mice. Many
brain regions contribute to the maintenance of sleep/wake
architecture.27 Due to the observed decrease in REM and
NREM sleep as well as decreased sleep bouts in P301S mice,
we analyzed tau pathology in two brain regions known to
play a substantial role in generating REM and NREM sleep.
The SLD is a REM-generating region located in the pons/
brainstem (Fig. 3A) and loss of glutamatergic neurons in
this region results in decreased REM sleep.28,29 P301S mice
displayed a significant increase in tau pathology in the SLD
at 9 and 11 months of age, the ages at which REM sleep was
decreased in these mice (Fig. 3B, one-way ANOVA,
P < 0.0001). Furthermore, SLD AT8 staining was negatively
correlated with total REM sleep time (Fig. 3C, Pearson r,
P < 0.0001). The GABAergic PZ, located in the brainstem
(Fig. 3D), is a slow wave sleep- or NREM sleep-promoting
region.30 P301S mice showed a significant increase in PZ
tau pathology at 11 months of age, the same age at which
NREM sleep time was significantly decreased (Fig. 3E, oneway ANOVA, P < 0.0001). PZ AT8 pathology was also negatively correlated with total NREM sleep time (Fig. 3F,
Pearson r, P < 0.0001). These results suggest that brainstem
tau pathology may play a role in the sleep loss observed in
P301S mice. Due to the global neuronal expression of the
P301S Tau transgene and progressive pathology development in P301S mice, correlation between sleep time and tau
pathology was not limited to these two brainstem regions.
However, AT8 pathology in the entorhinal cortex, a forebrain region heavily affected with tau pathology, as well as
the piriform cortex did not correlate with REM or NREM
sleep times in P301S mice (data not shown, Pearson r,
P > 0.05). The entorhinal cortex is well studied in AD and
is an early location of tau pathology progression in P301S
mice as well as human forebrain AD tau pathology.9,24 The
lack of association between sleep time and entorhinal or piriform cortex tau pathology further strengthens the possible
role of brainstem pathology in P301S sleep disturbances.

P301S Tau tg mice exhibit changes in EEG
delta and theta power
Figure 1. P301S Tau tg mice have decreased sleep that worsens
with age. Analysis of the average minutes/hour spent in wake (A),
REM sleep (B), and NREM sleep (C) for P301S and WT mice at 3
(n = 6), 6 (n = 9), 9 (n = 11 P301S, 10 WT), and 11 months of
age (n = 14). P301S mice had a significant loss of REM sleep at
9 months of age that worsened at 11 months (B). Eleven-monthold P301S mice also spent significantly less time in NREM sleep
and increased time in wake (A and C). **P < 0.01, ***P < 0.001,
****P < 0.0001. Student’s t-test at each age. All values represent
mean  SEM. REM, rapid eye movement; NREM, non-REM; WT,
wild-type.

EEG power from 1 to 20 Hz was determined for wake,
REM, and NREM vigilance states in P301S and WT mice.
No differences in EEG power were observed at 3 months
of age between P301S and WT mice (Fig. 4A–C). At
6 months of age, P301S NREM EEG power was
significantly increased in the delta frequencies (1–4 Hz)
compared to WT but wake and REM sleep were not
significantly altered (Fig. 4D–F, two-way ANOVA, NREM
interaction: P = 0.019, genotype: P < 0.0001). P301S
NREM EEG delta power remained significantly increased
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Figure 2. Wake, REM, and NREM bouts are altered in P301S mice. The number of wake (A), REM (B), and NREM (C) bouts was significantly
decreased in P301S mice compared to WT mice at 9 (n = 11 P301S, 10 WT) and 11 months of age (n = 14) but not at 3 (n = 6) and 6 months
(n = 9). (D) Wake bout duration was significantly increased at 9 and 11 months of age. (E) P301S REM bout duration was unchanged at 3, 6,
and 9 months of age but significantly decreased at 11 months. (F) P301S NREM bout duration was significantly increased at 9 months of age but
unchanged at 3, 6, and 11 months. *P < 0.05, **P < 0.01, ****P < 0.0001. Student’s t-test at each age. All values represent mean  SEM.
REM, rapid eye movement; NREM, non-REM; WT, wild-type.

at 9 months of age and REM sleep EEG power was also
significantly increased in the theta frequencies (4–8 Hz)
(Fig. 4H and I, two-way ANOVA, REM interaction:
P = 0.0179, NREM interaction: P = 0.0005, REM and
NREM genotype: P < 0.0001). Wake EEG power was not
affected at 9 months of age (Fig. 4G). However, at
11 months of age, P301S mice showed a marked and significant decrease in delta EEG power during wake and
NREM sleep, and theta EEG power during REM sleep
compared to WT mice (Fig. 4J–L, two-way ANOVA,
Wake interaction: P = 0.0031, REM interaction: P =
0.001, NREM interaction: P = 0.0163, all genotype: P <
0.0001). EEG power in WT mice did not change with age
(Fig. 5A–C) and is therefore not responsible for the
observed changes in P301S EEG power. However, in
P301S Tau tg mice, 11-month-old animals had significantly decreased EEG power compared to all other age
points in the delta and theta frequencies of wake and
NREM sleep and in theta frequencies only for REM sleep
(Fig. 5D–F, two-way ANOVA, all interaction and age:
P < 0.0001). These measures were not significantly different when comparing 3, 6, and 9 month P301S mice.

Cortex volume is associated with EEG power
in P301S Tau tg mice
P301S Tau tg mice have neurodegeneration and develop
brain atrophy beginning around 8 months of age that
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results in loss of cortex volume by 12 months.24 To test
if the observed decrease in P301S EEG power at
11 months of age is associated with atrophy we analyzed
hemispheric cortical volume at 3, 6, 9, and 11 months
of age. In this study, 11-month-old P301S mice had significantly decreased cortical hemispheric volume compared to 3- and 6-month-old P301S mice, the same age
at which decreased EEG power was observed in these
mice (Fig. 6A, one-way ANOVA, P < 0.0012). Furthermore, cortical hemispheric volume was significantly correlated with NREM EEG delta power in P301S mice of
all ages combined, demonstrating a possible interaction
between cortical volume and EEG power (Fig. 6B, Pearson r, P = 0.0002,). NREM delta power was analyzed
due to the profound and early changes observed at this
frequency range in P301S mice (Fig. 4). When analyzed
at independent age points, P301S cortical hemispheric
volume was significantly correlated with NREM delta
power at 11 month of age, but this correlation was not
significant at 9 months (Fig. 6C and D, Pearson r,
11 months: P = 0.0005, 9 months: P = 0.1345). The
observed correlation at 11 months of age when EEG
power is significantly decreased but not at 9 months
when EEG power is elevated suggests that neurodegeneration-induced brain atrophy may play a role in the loss
of EEG power observed at 11 months of age but may
not explain the increased EEG power observed at earlier
time points.
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Figure 3. Decreased REM and NREM sleep in P301S Tau tg mice is associated with tau pathology development in sleep regulating regions of the
brain. (A) Representative image of the SLD, a REM sleep-generating region of the brain. (B) AT8 staining in the SLD was significantly increased at
9 (n = 11) and 11 (n = 12) months of age compared to 3 (n = 8) and 6 (n = 11) months. (C) Time in REM sleep was negatively correlated with
AT8 SLD staining (n = 38). (D) Representative image of the PZ, a slow wave/NREM sleep-promoting region. (E) AT8 staining in the PZ was
significantly increased at 11 month of age and (F) NREM sleep time negatively correlated with AT8 PZ staining. *P < 0.05, **P < 0.01,
***P < 0.001. One-way ANOVA with Tukey’s post hoc, all values represent mean  SEM (B and E). Pearson r (C and F). All AT8 staining values
were normalized to a batch control. REM, rapid eye movement; NREM, non-REM; SLD, sublaterodorsal area; PZ, parafacial zone; ANOVA, analysis
of variance.

Eleven-month-old P301S Tau tg mice
maintain homeostatic response to sleep
deprivation
Sleep is homeostatically regulated in that prolonged wakefulness leads to a compensatory increase in sleep as well
as increased NREM sleep slow wave activity.27 Since
P301S mice have decreased sleep time and decreased EEG
power at 11 months of age, we further characterized
homeostatic sleep response in these mice as another way
to assess their sleep/wake cycle. Sleep and wake were analyzed in P301S and WT mice following 6 h of manual
sleep deprivation. When sleep and wake time was normalized to the previous baseline day of recording, 11-monthold P301S mice had less of a decrease in wake than WT
mice, but changes in REM and NREM sleep were not significantly different (Fig. 7A–C). Eleven-month P301S
mice maintained an elevated level of sleep similar to controls following sleep deprivation. Furthermore, NREM
EEG power normalized to the previous day was increased
in a similar manner in the delta frequencies of both 11month-old P301S and WT mice (Fig. 7D). These results
demonstrate that even at advanced stages of disease when

sleep time and EEG power is significantly decreased,
P301S mice maintain homeostatic sleep responses.

Discussion
Sleep is an important biological function that is commonly altered in neurodegenerative disease.18,31 Despite
the importance of sleep and the prevalence of sleep disturbances observed across tauopathies, little is known
about the effects of disease associated tau aggregation
throughout the brain on sleep. Here, we demonstrate that
a mouse model expressing human P301S Tau throughout
the brain and tau pathology in both forebrain and brainstem regions, exhibits changes in sleep with disease progression. We have shown that P301S mice have a
progressive decrease in sleep and increase in wakefulness,
and that loss of sleep is associated with tau pathology in
brainstem sleep regulating regions. Particularly interesting
is the early decrease in REM sleep. Furthermore, P301S
mice have changes in EEG power over time that are associated with decreased cortical volume. Despite changes in
sleep and EEG power, P301S mice maintain homeostatic
response to sleep deprivation.
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Figure 4. EEG power is altered in P301S Tau tg mice. Analysis of EEG power during wake, REM sleep, and NREM sleep at 3 (n = 6 P301S and
WT), 6 (n = 8 P301S [D and E], n = 7 P301S [F], n = 8 WT), 9 (n = 11 P301S, n = 10 WT), and 11 months of age (n = 12 P301S [J and L],
n = 11 P301S [K], n = 12 WT) in P301S and WT mice. EEG power was not significantly altered at 3 months of age in wake (A), REM (B) or NREM
sleep (C). EEG power was unchanged at 6 months of age during wake (D) and REM sleep (E), but power in P301S mice was significantly
increased during NREM sleep in the delta frequencies (1–4 Hz) (C). Nine-month-old P301S mice exhibited significantly increased EEG power in the
theta frequencies (4–8 Hz) during REM sleep (H) and delta frequencies in NREM sleep (I) but power was not significantly affected during wake
(G). At 11 months of age, P301S delta EEG power was significantly decreased in wake (J) and NREM sleep (L) and theta EEG power significantly
decreased during REM sleep (K). *P < 0.05, **P < 0.01, ***P < 0.001. Two-way ANOVA with Bonferroni post hoc. All values represent
mean  SEM. EEG, electroencephalography; REM, rapid eye movement; NREM, non-REM; WT, wild-type; ANOVA, analysis of variance.

Changes in sleep time and association with
brainstem sleep regions
FTD, PSP, and AD patients all have decreased sleep and
we have demonstrated that this phenotype is recapitulated
in the P301S tauopathy mouse model.3–7 The progression
of sleep disturbances over time has not been reported in
tauopathy mouse models and we show here that sleep
deficits worsen with age and disease progression. Sleep
analysis of a different FTD model expressing tau specifically in the forebrain (PLB2Tau) has also reported loss of
NREM sleep and increases in wake, but unlike P301S
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mice shown here, changes in REM sleep were not
observed in PLB2Tau mice.20 Sleep changes in PLB2Tau
mice support our findings that tau pathology is sufficient
to induce sleep changes and further suggests that the
REM sleep disruption we observe in P301S mice may be
due to brainstem pathology present in P301S but not
PLB2Tau models.20 This is supported by our observation
that AT8-positive tau pathology in the SLD is negatively
correlated with REM sleep time. Tau knock-out mice also
only show changes in wake and NREM sleep, suggesting a
role for tau pathology, and not tau loss of function, in
REM sleep disruption.23 In addition to REM sleep, areas
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Figure 5. EEG power does not change with age in WT mice but is significantly decreased in 11-month-old P301S mice. WT mice at 3, 6, 9, and
11 months of age showed no changes in wake (A), REM (B), or NREM (C) EEG power with age. However, P301S mice had significantly decreased
wake (D), REM (E), and NREM (F) EEG power at 11 months of age compared to 3, 6, and 9 month P301S mice. *P < 0.05, **P < 0.01,
***P < 0.001. Two-way ANOVA. All significance compared to 11 month P301S mice by Bonferroni post hoc (D-F). All values represent
mean  SEM. EEG, electroencephalography; REM, rapid eye movement; NREM, non-REM; ANOVA, analysis of variance; WT, wild-type.

in the brainstem also regulate NREM sleep and wake.
Despite the presence of NREM decreases in PLB2Tau forebrain expressing mice, our results highlight that the effect
of tau pathology on brainstem regions such as the PZ,
which negatively correlated with NREM sleep time in
P301S mice, should not be overlooked.20
The brainstem and other sleep-regulating regions of the
brain are affected by tau pathology in taupathies.9–12,32 In
AD, abnormal tau pathology can be seen in brainstem
sleep/wake regions such the LC, dorsal raphe, and parabrachial nucleus as well as hypothalamic sleep regions prior to

the onset of cortical tau or amyloid.9–11 Other sleep
regions, such as the pedunculopontine tegmental nucleus
(PPT), develop tau pathology in clinical stages of disease.17
In AD, neuronal loss and tau neurofibrillary tangles occur
in the PPT, but not amyloid pathology.13,17 In PSP, REM
sleep is highly affected and loss of REM sleep is suggested
to result from tau pathology-induced degeneration of the
PPT, demonstrating the importance of brainstem regions
in sleep and their vulnerability to tau pathology.6,13 Early
tau abnormalities in the brainstem are not recapitulated in
mouse models and despite pathological analysis of some
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Figure 6. Cortical hemispheric volume decreases with age and correlates with NREM delta power in P301S Tau tg mice. (A) Analysis of cortical
hemispheric volume in 3 (n = 8), 6 (n = 11), 9 (n = 11), and 11 (n = 12) month-old P301S mice showed a significant decrease at 11 months.
Cortical hemispheric volume was significantly correlated with NREM delta power when all P301S mice ages were combined (B, n = 36) and
11 months of age only (D, n = 12), but not at 9 months of age (C, n = 11), suggesting that cortical volume loss may play a role in the decreased
EEG power observed at 11 months of age. **P < 0.01. One-way ANOVA with Tukey’s post hoc, all values represent mean  SEM (A). Pearson r
(B–D). NREM, non-rapid eye movement; EEG, electroencephalography; ANOVA, analysis of variance.

Figure 7. P301S Tau tg mice maintain homeostatic response to sleep
deprivation. Eleven-month-old P301S and WT mice (n = 6) were sleep
deprived for 6 h and EEG analyzed for 5 h following sleep deprivation.
All data were normalized to the time matched previous day of recording.
Time spent in wake (A), REM sleep (B), and NREM sleep (C) following
sleep deprivation. (D) NREM EEG power was similarly increased in the
delta frequencies of both P301S and WT mice. *P < 0.05. Student’s
t-test (A–C). Two-way ANOVA (D). All values represent mean  SEM.
EEG, electroencephalography; REM, rapid eye movement; NREM, nonREM; ANOVA, analysis of variance; WT, wild-type.

brainstem regions in human clinical AD, many specific
sleep regions, including the SLD and PZ analyzed here,
have yet to be studied. However, the association of pathology onset in sleep-generating brainstem regions with the
onset of sleep loss as well as significant correlation between
these factors is strengthened by the proximity of these brain
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regions to others known to be affected by AD tau pathology
and is suggestive of a role for brainstem tau pathology in
P301S sleep disturbances.
Here, we analyzed the SLD and PZ based on their ability to modulate REM and NREM sleep and our results
demonstrate, for the first time, the likely importance of
brainstem tau pathology in tau-induced sleep deficits.
Eliminating glutamatergic signaling in the SLD significantly decreases REM sleep by ~40%, similar to what was
observed here in P301S mice.28 However, SLD Vglut
knockdown also increases sleep bout frequency, which we
did not observe in the P301S Tau tg model.28 These similarities and differences demonstrate that tau pathology
may affect many regions of the brain, a combination of
which is likely responsible for sleep/wake changes observed
in P301S mice. In P301S mice we also observed fewer sleep
bouts as well as fewer and longer wake bouts. The
decreased transition to sleep from wake suggests breakdown of sleep-promoting/wake-inhibiting pathways. The
PZ promotes slow wave sleep by inhibiting the wake-promoting parabrachial nucleus and its basal forebrain cortical circuit.30 Thus, loss of PZ function is a possible
mechanism for tau pathology-induced decrease in sleep
bouts and this is supported by the negative correlation
between NREM sleep time and PZ tau pathology. It is
likely that other sleep regions of the brain, including
brainstem and thalamic regions, are also affected by tau
pathology and contribute to the observed sleep disturbances. More work is needed to determine if tau pathology in the SLD, PZ, or other sleep regions alone is
sufficient to induce changes in sleep and if tau pathologyinduced sleep changes can affect disease progression.

EEG power and cortical volume
Here, we demonstrated that P301S mice have changes in
EEG power, with elevated EEG power compared to
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WT at 6 and 9 months of age and significantly decreased
power at 11 months. These changes are not due to
changes in WT EEG power but to a significant decrease
in P301S EEG power at 11 months of age that corresponds with a significant decrease in cortical volume.
Changes in EEG power over time have not previously
been reported in tauopathy mice. Increased EEG power
during disease progression could represent a compensatory response to pathological tau aggregation. Although
more work is needed to understand the mechanism of
increased power in P301S mice, the observed correlation
between cortex volume and EEG power demonstrates that
neurodegenerative cortical atrophy may be responsible for
the severe decrease in EEG power observed in 11-monthold P301S mice. Furthermore, we have shown that even
at severe stages of disease when sleep time and EEG
power are decreased, P301S mice maintain a homeostatic
response to sleep deprivation. We surprisingly observed
similar increases in REM and NREM sleep time as well as
increased NREM slow wave delta power in aged P301S
and WT mice. The mechanisms and exact sleep factors
resulting in homeostatic regulation of sleep are not fully
elucidated. Adenosine build up and signaling in the basal
forebrain and other regions is known to play a role, but
it is likely not the only factor.27 Despite this, alterations
in sleep and EEG power are well documented.27 The
maintenance of homeostatic response of NREM EEG
power in P301S aged mice may indicate that despite
regional brain atrophy and decreased EEG power, the
existing neurons and neural networks maintain the ability
to respond and increase activity to homeostatic sleepdrive cues.

Conclusions and Implications
We have demonstrated for the first time that tau pathology throughout the brain, including both the forebrain
and brainstem, can progressively cause sleep disruption
and changes in EEG power over time. We have further
shown that the brainstem may play an important role in
the development of sleep disturbances. Previously, Ab
pathology has been shown to not only induce sleep disruption but pathology is also accelerated by sleep deprivation and decreased by sleep improvement.22,25,33
Therefore, tau-induced decreases in REM and NREM
sleep may directly affect amyloid AD pathology, interact
with Ab-induced sleep problems, and could play a role in
worsening disease. In the brain interstitial fluid, levels of
tau, like Ab, are increased with elevated neuronal activity,
suggesting that increased wakefulness may elevate tau
secretion and disease spreading in tauopathies.25,34,35
Whether changes in sleep affect tau pathology directly, as
has been seen with Ab, remains to be studied.25,33

Altered Sleep and EEG Power in P301S Tau Mice

However, even if changes in sleep do not directly affect
tau pathology, decreasing sleep could play a role in accelerating other AD disease mechanisms such as amyloid
pathology and secondarily affect tau. Furthermore, quantitative assessment of sleep and EEG power in the P301S
Tau tg model could be a useful method to functionally
assess the effects of anti-tau and other neuroprotective
therapies, in addition to evaluation of cognitive and
motor outcomes. P301S mice and the sleep disturbances
observed could therefore serve as a valuable way to assess
for disease progression and as a functional tool in assessing disease outcome.
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